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Risk Model Development and Validation for Prediction of Coronary
Artery Aneurysms in Kawasaki Disease in a North American
Population
Mary Beth F. Son, MD; Kimberlee Gauvreau, ScD; Adriana H. Tremoulet, MD, MAS; Mindy Lo, MD, PhD; Annette L. Baker, RN, MSN, PNP;
Sarah de Ferranti, MD, MPH; Fatma Dedeoglu, MD; Robert P. Sundel, MD; Kevin G. Friedman, MD; Jane C. Burns, MD;
Jane W. Newburger, MD, MPH
Background-—Accurate prediction of coronary artery aneurysms (CAAs) in patients with Kawasaki disease remains challenging in
North American cohorts. We sought to develop and validate a risk model for CAA prediction.
Methods and Results-—A binary outcome of CAA was defined as left anterior descending or right coronary artery Z score ≥2.5
at 2 to 8 weeks after fever onset in a development cohort (n=903) and a validation cohort (n=185) of patients with Kawasaki
disease. Associations of baseline clinical, laboratory, and echocardiographic variables with later CAA were assessed in the
development cohort using logistic regression. Discrimination (c statistic) and calibration (Hosmer-Lemeshow) of the final model
were evaluated. A practical risk score assigning points to each variable in the final model was created based on model
coefficients from the development cohort. Predictors of CAAs at 2 to 8 weeks were baseline Z score of left anterior descending
or right coronary artery ≥2.0, age <6 months, Asian race, and C-reactive protein ≥13 mg/dL (c=0.82 in the development cohort,
c=0.93 in the validation cohort). The CAA risk score assigned 2 points for baseline Z score of left anterior descending or right
coronary artery ≥2.0 and 1 point for each of the other variables, with creation of low- (0–1), moderate- (2), and high- (3–5) risk
groups. The odds of CAAs were 16-fold greater in the high- versus the low-risk groups in the development cohort (odds ratio,
16.4; 95% CI, 9.71–27.7 [P<0.001]), and >40-fold greater in the validation cohort (odds ratio, 44.0; 95% CI, 10.8–180
[P<0.001]).
Conclusions-—Our risk model for CAA in Kawasaki disease consisting of baseline demographic, laboratory, and echocardiographic
variables had excellent predictive utility and should undergo prospective testing. ( J Am Heart Assoc. 2019;8:e011319.
DOI: 10.1161/JAHA.118.011319.)
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K awasaki disease (KD) is the leading cause of acquiredpediatric heart disease in developed nations. Treatment
with intravenous immunoglobulin (IVIG) reduces the risk of
coronary artery aneurysms (CAAs), a potentially devastating
long-term complication of KD, by 5-fold.1 The clinical window
in which to diagnose and treat KD and thereby prevent long-
term sequelae is brief, as children with KD should be treated
within 10 days of fever onset. Accordingly, early identification
of children who are at high risk for CAA is paramount, yet
instruments for such identification have remained elusive in
non-Japanese populations. We previously assessed the clinical
utility of established Japanese risk scores for predicting CAA
development in a Western population and found them to be
poorly predictive.2 In contrast, coronary artery dimensions
adjusted for body surface area (Z scores) at first diagnosis of
KD, ie, baseline Z scores, were the most predictive risk factor
for later CAA. In this study, we sought to create a risk model
for CAA prediction with development and validation cohorts
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(VCs), considering baseline Z score as well as other clinical
and laboratory variables previously demonstrated to be
predictive of worse outcomes in KD.
Methods
Permission to use the validation data set was obtained from
the Ancillary Studies Committee of the Pediatric Heart
Network. This data set has since been made publicly available
by the Pediatric Heart Network.3 Data from the development
cohort (DC) is not available because of privacy concerns.
Development Cohort
The development data set for risk score creation was
constituted from retrospective review of consecutive patients
treated for KD at 2 academic centers. Specifically, we
included all pediatric patients with KD (maximum age
<19 years) treated at Boston Children’s Hospital from January
2006 to May 2014 and at Rady Children’s Hospital from July
1989 to May 2014. Patients were diagnosed with either
complete KD (fever for ≥4 days [rarely ≥3 days] and ≥4
classical criteria for KD) or incomplete KD (<4 criteria with
compatible laboratory and/or echocardiographic findings).1
All patients were treated with IVIG and aspirin between days 3
through 10 of illness, with day 1 defined as the first day of
fever. Patients were excluded if they: (1) had been transferred
to either center for a second opinion, (2) had a prior episode
of KD, (3) lacked laboratory data before 10 days of illness, (4)
had laboratory examinations performed ≥1 day after IVIG
administration, or (5) lacked echocardiographic data either at
baseline (pre-IVIG or <2 days after IVIG administration) or
within 2 to 8 weeks of illness. If a patient had >1 echocar-
diogram within 2 to 8 weeks after fever onset, we used the
study that had the largest left anterior descending (LAD)
artery and right coronary artery (RCA) measurements from the
time period. Approvals from institutional review boards with
waivers of informed consent were obtained for this project.
Validation Cohort
The VC was assembled during a National Heart, Lung, and
Blood Institute Pediatric Heart Network clinical trial at 8 North
American centers, which assessed the role of intravenous
methylprednisolone in the primary treatment of KD.4 Partic-
ipants in the trial had been well characterized with respect to
demographic, laboratory, and echocardiographic data.
Because of the trial design, CAA as the outcome was
assessed specifically at 5 weeks (window day 28 through day
42) after randomization. All exclusion criteria applied to the
DC were applied to the VC.
Data Obtained
We extracted demographic data, KD criteria, other medical
variables, and laboratory data from electronic medical records
and clinical databases, and from a deidentified research
database for the validation data set. The following variables
were assessed in the risk model: demographic factors,
including age, sex, race, ethnicity, and incomplete versus
complete criteria for KD; clinical factors including days of
fever at diagnosis and need for treatment beyond 1 dose of
IVIG (termed IVIG resistance); and baseline laboratory studies
including white blood cell count, neutrophil count, hemoglo-
bin, hematocrit, platelets, C-reactive protein (CRP), sodium,
aspartate aminotransferase, alanine aminotransferase, albu-
min, and total bilirubin. Race and ethnicity were included as
variables because prior studies have indicated that patients of
Asian descent5,6 or Hispanic ethnicity6 are at increased risk
for poor coronary outcomes.6
Echocardiographic data were collected from reports pro-
duced at the time of the study. Using the reported measure-
ments of the LAD artery and RCA, Z scores for the proximal
LAD artery and proximal RCA were calculated using Z score
equations derived from previously described normative data.7
Prior studies from our institution have shown high interob-
server and intraobserver reliability for proximal LAD artery and
RCA measurement.8,9 The maximum Z score at baseline was
defined as the larger of the proximal LAD artery and the
proximal RCA Z scores. Children were classified as having the
outcome of CAA if they had a Z score ≥2.5 in either the LAD
artery or RCA between 2 and 8 weeks after illness onset.
Statistical Analyses
Continuous variables are summarized as median with
interquartile range or range, as noted, or as mean with SD.
Categorical variables are summarized with frequencies and
Clinical Perspective
What Is New?
• We developed and validated a practical risk score composed
of baseline demographic, laboratory, and echocardiographic
variables that has high predictive utility for future develop-
ment of coronary artery aneurysms in patients with
Kawasaki disease.
What Are the Clinical Implications?
• An instrument to stratify risk of future coronary artery
aneurysms in patients who present with acute Kawasaki
disease provides the opportunity to intensify primary
therapy and for closer echocardiographic surveillance.
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percentages. In the DC, associations of baseline clinical,
laboratory, and echocardiographic measurements with the
binary outcome of CAA within 2 to 8 weeks of fever onset
were assessed using Fisher exact test for categorical
variables and the Wilcoxon rank sum test or unpaired t test
for continuous variables. The ability of each measurement to
discriminate between patients who did and did not develop
CAA within 2 to 8 weeks was quantified using the c statistic.
Variables with P<0.20 in unadjusted analyses were con-
sidered for inclusion in a multivariable model. Multivariable
logistic regression was performed using forward stepwise
selection. Cut points were considered for continuous risk
factors; the cut point resulting in the highest c statistic was
chosen. Only variables that were both statistically significant
at the 0.05 level by the likelihood ratio test and that improved
the c statistic were retained in the final multivariable model.
Goodness-of-fit of the model was assessed using the Hosmer-
Lemeshow test. The multivariable model derived in the DC
was then applied to the VC; discrimination of the model was
evaluated by the c statistic, and goodness-of-fit by the
Hosmer-Lemeshow test.
To calculate a risk score for each patient, the coefficients
from the final multivariable logistic regression model in the
DC were used to assign point values for each covariate in the
model and the points were then summed for each patient.
Higher scores indicated a greater number of risk factors and
therefore higher presumed risk of CAA within 2 to 8 weeks of
fever onset. The risk scores were used to define low-,
moderate-, and high-risk categories, and risk category was
used as the predictor in logistic regression models with the
outcome of CAA within 2 to 8 weeks of fever onset for both
the DC and the VC.
Results
The DC consisted of 903 patients with KD (300 patients from
Boston Children’s Hospital and 603 patients from the
University of California at San Diego), and the VC had 185
patients with KD. There was no overlap of patients between
the 2 cohorts. The cohorts differed in regards to race,
ethnicity, and number of clinical criteria for KD at diagnosis,
but did not differ significantly in other baseline demographic
or clinical variables (Table 1). Baseline laboratory studies and
echocardiographic measurements were also similar between
cohorts with the exception of hemoglobin, albumin, and
baseline RCA Z score (Table 2). In the DC, the median time
from fever onset to baseline echocardiogram was 6 days
[interquartile range, 5–8]. The median time between baseline
and outcome echocardiograms was 25 days [interquartile
range, 14–37]. The percentage of patients with CAA was
similar between the cohorts: 13.0% (n=117) in the DC and
13.5% (n=25) in the VC.
We first analyzed univariate associations between baseline
variables and presence of CAA at 2 to 8 weeks after illness
onset in the DC. The outcome of CAA was highly associated
with younger age at fever onset; Asian race (one or both
parents of Asian descent); higher white blood cell count and
CRP; lower hemoglobin, hematocrit, and albumin; and max-
imum Z score at baseline of the RCA or LAD artery (≥2.00)
(Table 3).
For the multivariable model, independent predictors
included maximum Z score at baseline ≥2.00, age at fever
onset <6 months, Asian race, and CRP ≥13 mg/dL. The
model had a c statistic of 0.82 (Hosmer-Lemeshow, P=0.816).
Application of the multivariable model created in the
Table 1. Demographic and Clinical Characteristics of the DC
and VC
Characteristic
DC (n=903)
No. (%) or
Median
(Range)
VC (n=185)
No. (%) or
Median
(Range) P Value
Age at fever onset, y 2.8
(0.1–15.5)
3.0
(0.2–12.3)
0.912
Male sex 566 (63) 115 (62) 0.934
Race
White 530 (60) 105 (57) <0.001
Black 55 (6) 37 (20)
Asian 139 (16) 26 (14)
Other 18 (2) 4 (2)
>1 race reported 143 (16) 12 (7)
Any Asian race
reported*
202 (22) 31 (17) 0.095
Hispanic 244 (27) 29 (16) 0.001
No. of clinical criteria reported
≤3 147 (17) 7 (4) <0.001
4 520 (59) 119 (64)
5 208 (24) 59 (32)
Days of fever at diagnosis 6 (3–10) 6 (4–10) 0.007
IVIG retreatment 141 (16) 24 (13) 0.431
CAAs at 2 to 8
wk after illness onset
117 (13) 25 (13.5)† 0.811
Small CAAs
(Z score ≥2.5–5)
75 (8) 19 (10)
Medium CAAs
(Z score ≥5 to ≤10)
14 (2) 4 (2)
Large or giant CAAs
(Z score ≥10 or absolute
dimension ≥8 mm)
28 (3) 2 (1)
CAAs indicates coronary artery aneurysms; DC, development cohort; IVIG, intravenous
immunoglobulin; VC, validation cohort.
*One or both parents report Asian descent.
†As measured at 5 weeks, per Pediatric Heart Network trial protocol.
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development data set to the VC revealed a c statistic of 0.93
(Hosmer-Lemeshow, P=0.211), but only the maximum Z score
at baseline was statistically significant.
Using the demographic and clinical characteristics yielded
by the logistic regression, a simple scoring model was
constructed in the DC. For each patient, 2 points were
assigned if the maximum Z score at baseline was ≥2.00, 1
point if age at fever onset was <6 months, 1 point if Asian
race was reported, and 1 point if baseline CRP was ≥13 mg/dL.
A 3-tier scoring system was determined based on the sum of
points per patient: 0 to 1 point (low risk), 2 points (moderate
risk), and 3 to 5 points (high risk). Patients in the DC and VC
had a similar distribution of numeric values (0–5 points) for
the risk score (Table 4). In the DC, 16.4% of patients had high-
risk scores (numeric values from 3 to 5), and 41.2% of these
patients had CAAs at 2 to 8 weeks after fever onset. Similarly,
Table 2. Baseline Laboratory and Echocardiography Studies of DC and VC
Characteristic DC (n=903) VC (n=185) P Value
Laboratory studies: median (interquartile range)
White blood cell count, cells 9103/mm3 13.5 (10.5–17.3) 13.3 (10.1–16.6) 0.406
Neutrophils, % 59 (47–71) 61 (41–71) 0.328
Hemoglobin, g/dL 11.1 (10.4–11.8) 10.9 (10.1–11.7) 0.047
Hematocrit, % 32.4 (30.7–34.5) 32.0 (30.0–34.0) 0.066
Platelets, cells 9103/mm3 366 (287–457) 389 (303–464) 0.190
CRP, mg/dL 7.9 (4.5–15.2) 7.2 (4.0–15.3) 0.295
Sodium–mmol/L 135 (133–137) NA
AST, U/L 36 (26–55) NA
ALT, U/L 38 (19–103) 32 (16–84) 0.062
Albumin, g/dL 3.6 (3.2–4.0) 3.3 (2.8–3.7) <0.001
Total bilirubin, mg/dL 0.3 (0.2–0.7) NA
Baseline echocardiography, meanSD
RCA Z score 0.941.37 1.211.39 0.019
LAD artery Z score 1.181.66 1.131.55 0.665
Maximum Z score of the LAD artery and RCA 1.611.59 1.691.50 0.503
RCA Z score
≥2.00 148 (16) 36 (20) 0.277
≥2.50 88 (10) 26 (14) 0.083
≥3.00 57 (6) 15 (8) 0.327
LAD artery Z score
≥2.00 195 (22) 40 (22) 1.000
≥2.50 122 (14) 29 (16) 0.415
≥3.00 76 (8) 17 (9) 0.772
Maximum baseline Z score
≥2.00 264 (29) 55 (30) 0.929
≥2.50 170 (19) 42 (23) 0.223
≥3.00 110 (12) 27 (15) 0.394
Baseline CAAs
Small CAAs (Z score ≥2.5–5) 149 (16) 38 (21) 0.394
Medium CAAs (Z score ≥5 to ≤10) 15 (2) 4 (2)
Large or giant CAAs (Z score ≥10 or
absolute dimension ≥8 mm)
6 (1) 0 (0)
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; CAAs, coronary artery aneurysms; CRP, C-reactive protein; DC, development cohort; LAD, left anterior
descending; NA, not available; RCA, right coronary artery; VC, validation cohort.
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12.4% of the VC had risk scores from 3 to 5, and over half of
these patients (52.2%) had CAA. Compared with patients who
had a risk score of 0 to 1, those whose risk score was ≥3 in
the DC had a much higher risk of having CAAs (odds ratio,
16.4; 95% CI, 9.71–27.7 [P<0.001]) (Table 5). The odds of
having CAA in those with a risk score of 2 versus 0 to 1 was
also higher (odds ratio, 5.4; 95% CI, 3.09–9.5 [P<0.001]).
Analysis of the risk score in the VC revealed that the high-risk
group had a very high odds ratio of CAA as compared with the
low-risk group (odds ratio, 44.0; 95% CI, 10.8–180 [P<0.001]).
However, the CIs were widened by the low prevalence
outcome, with only 3 patients with CAAs in the low-risk group
in the VC. The c statistic for the risk score in the DC was 0.79
(Hosmer-Lemehsow, P=0.999). When the risk score was
applied to the VC, the c statistic rose to 0.85 (Hosmer-
Lemehsow, P=0.999).
Discussion
Although the majority of children with KD have excellent
clinical outcomes after treatment with a single dose of IVIG in
the first 10 days of illness, 25% of children and >50% of
infants younger than 6 months with KD have Z scores ≥2.5 in
the first 12 weeks of illness in both North American and
Japanese populations.7,10–12 Approximately 1% of patients
with KD progress to giant aneurysms that can cause ischemic
heart disease, including angina, myocardial infarction, and
sudden death. Adjuvant immunomodulatory therapies, admin-
istered together with standard IVIG, may further lower the
incidence of CAA. To institute such therapies early enough to
prevent damage of the coronary arterial wall, high-risk
children must be identified at the time of diagnosis. Tools
for risk stratification of patients with KD at presentation have
proven elusive, however. A prior risk score created in North
America included presence of fever following IVIG adminis-
tration,13 which is less helpful in determining at diagnosis who
would benefit from intensification of initial treatment. There
are several Japanese risk-scoring systems for predicting IVIG
resistance, which is highly associated with CAA, using
different clinical and laboratory values. The Kobayashi score
Table 3. Associations With CAAs in the DC
Univariate Associations in DC With CAAs
(n=117, 13.0%)
Characteristic Odds Ratio (95% CI) P Value
Age at fever onset <6 mo 3.71 (2.06–6.68) <0.001
Asian race reported 2.29 (1.51–3.47) <0.001
Days of fever (↑ 1 d) 1.11 (0.99–1.23) 0.063
Maximum Z score at
baseline (↑ 1 Z score unit)
2.35 (1.97–2.79) <0.001
Maximum Z score at baseline ≥2.00 9.01 (5.81–14.0) <0.001
White blood cell count ≥16 cells/mm3 2.43 (1.64–3.61) <0.001
Hemoglobin <10.3 g/dL 1.98 (1.28–3.05) 0.002
Hematocrit <32 2.19 (1.47–3.27) <0.001
CRP ≥13 mg/dL 2.13 (1.41–3.21) <0.001
Albumin <3.2 g/dL 3.63 (2.23–5.92) <0.001
Final multivariable model: c statistic=0.82 (Hosmer-Lemeshow,
P=0.816)
Maximum Z score at baseline ≥2.00 9.82 (6.09–15.9) <0.001
Age at fever onset <6 mo 3.02 (1.5–6.06) 0.002
Any Asian race reported 1.95 (1.2–3.17) 0.007
CRP ≥13 mg/dL 2.06 (1.3–3.26) 0.002
CAAs indicates coronary artery aneurysms; CRP, C-reactive protein; DC, development
cohort.
Table 4. Risk Score* in the DC and VC
Risk Score No. (%) No. (%) With CAA
DC (n=903)
0 346 (38) 24 (4.1)
1 239 (26)
2 170 (19) 32 (18.8)
3 108 (12) 61 (41.2)
4 36 (4)
5 4 (<1)
VC (n=185)
0 79 (43) 3 (2.4)
1 45 (24)
2 38 (21) 10 (26.3)
3 18 (10) 12 (52.2)
4 5 (3)
5 0 (0)
CAAs indicates coronary artery aneurysm; DC, development cohort; VC, validation
cohort.
*Risk scoring: 2 points if maximum baseline Z score ≥2.00, 1 point if age at fever onset
younger than 6 months, 1 point if Asian race reported, 1 point if C-reactive protein
≥13 mg/dL.
Table 5. Three-Tier Risk Score
Risk Score (vs 0–1) Odds Ratio 95% CI P Value
Three-tier risk model in the DC (c statistic=0.79)
2 (moderate risk) 5.42 3.09–9.50 <0.001
3 to 5 (high risk) 16.4 9.71–27.7 <0.001
Three-tier risk model in the VC (c statistic=0.85)
2 (moderate risk) 14.4 3.72–55.8 <0.001
3 to 5 (high risk) 44.0 10.8–180 <0.001
DC indicates development cohort; VC, validation cohort.
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is now widely used in Japanese populations to stratify risk for
IVIG resistance and consists of easily accessible demographic
and laboratory values.14 Unfortunately, the Kobayashi score
did not accurately predict poor outcomes in non-Japanese
populations.2,15 Similarly, the other Japanese risk scores have
demonstrated good specificity but low sensitivity for predict-
ing IVIG resistance or CAA in North American children.15,16 In
contrast, baseline echocardiographic measurements have
shown promise for predicting CAA.2,7,17 We sought to develop
and validate a risk score for CAA in a North American
population of patients with KD using patient, laboratory, and
echocardiographic factors assessed at the time of presenta-
tion.
In our development data set, we found that a baseline
maximum Z score of the LAD artery or RCA ≥2, age at fever
onset of younger than 6 months, Asian race, and CRP
≥13 mg/dL at diagnosis were independent risk factors for
CAA in a multivariable regression analysis and yielded a c
statistic of 0.82. Each of these factors has been previously
associated with increased risk for IVIG resistance or CAA in
North American populations.1,2,18–20 The finding that age
younger than 6 months is highly predictive of CAA has been
recently demonstrated by Salgado et al.12 In that study, 43%
of infants younger than 6 months treated within the first
10 days of illness had dilated or aneurysmal coronary arteries
at baseline, and 19% of those whose coronary arteries had
normal dimensions at presentation went on to develop dilated
or aneurysmal coronary arteries within 8 weeks of diagnosis.
This finding underscores the importance of heightened
vigilance for KD in very young infants with prolonged fever,
even in the absence of diagnostic criteria.1 Asian race is not
only a risk factor for KD itself6,19 but also for a higher rate of
CAA.1,5,20 Of note, we classified children as Asian if they
selected it as the sole race or if they were of mixed Asian race
(ie, >1 race). We did not have further detailed information
regarding Asian race in either cohort (ie, South Asian versus
East Asian). In a retrospective study of coronary outcomes in
North America and Japan, Ogata and colleagues11 found that
when adjusting for age, sex, and treatment response,
Japanese race was associated with having a higher maximum
Z score of the LAD artery or RCA within the first 12 weeks of
illness. To our knowledge, there are no other studies that
directly compare coronary artery outcomes in Asians versus
non-Asians using standardized definitions. CRP has consis-
tently been found to be elevated in patients with KD and is a
component in the Kobayashi, Sano, and Egami risk scores for
prediction of IVIG resistance.14,21,22 In a recent study in a
Korean population, elevated CRP predicted both IVIG resis-
tance as well as coronary artery abnormalities.23 Furthermore,
CRP was noted to be higher in a North American population of
children who developed IVIG resistance.24 Given our prior
assessment of Japanese risk scores in North American
populations,2 we applied the Kobayashi, Egami, Sano, and
Harada risk scores to the DC and found c statistics ranging
from 0.54 to 0.61, which is commensurate with our prior
findings and far less predictive than our current model (c
statistic, 0.82).
Application of the multivariable model derived in the DC to
the VC yielded a c statistic of 0.93. In the VC, the baseline Z
score had the highest discrimination in the model, consistent
with prior studies underscoring the importance of baseline
echocardiographic measurements. We also devised a 3-tier
risk scoring system with high predictive utility using the
variables identified in the regression analysis to provide a
practical tool for early identification of patients at risk for
CAA. An advantage of our risk score is the easy accessibility
of the component variables at the time of KD presentation. As
we selected variables available at diagnosis, we did not
include differences in treatment regimens in our analysis.
Demographic risk factors are known at diagnosis, and
collection of laboratory values, such as CRP, as well as
baseline echocardiography, are the standard of care in KD. If
the risk score from the current study proves predictive in
other populations, it could be useful not only in tailoring
primary treatment of KD in children to their risk of CAA, but
also in providing a means of selecting high-risk children for
participation in clinical trials of intensified primary therapy. Of
note, the optimal adjunctive anti-inflammatory agent(s) used
together with IVIG in the primary treatment of high-risk KD is
controversial, with practice variation among practitioners and
centers.1,25,26 Last, patients who are identified as high risk
per our score may benefit from frequent (eg, twice weekly)
echocardiography during the initial illness until coronary
dimensions stabilize to detect abnormalities early enough to
treat more aggressively with immunosuppressive therapies.
Study Limitations
Our analyses were limited by the differences in data collection
between the DC and the VC. Data collection in the former was
part of routine clinical care, whereas data in the latter were
collected prospectively in the setting of a multicenter clinical
trial. The differences between the 2 cohorts in race, ethnicity,
and number of clinical criteria at diagnosis were likely the
result of regional differences in the populations and differ-
ences in treatment of patients with KD in a real-world setting
compared with a clinical trial, which uses strictly defined
selection criteria. Differences between the cohorts in labora-
tory values (hemoglobin and albumin) and baseline RCA Z
score may be caused by the smaller number of patients in the
VC. Differences between the cohorts in laboratory values
(hemoglobin and albumin) and baseline RCA Z score may be
attributable to the smaller number of patients in the VC.
Neither hemoglobin nor albumin were components in the
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multivariable model or risk score. The cohorts had similar
baseline maximum Z score, the echocardiographic variable in
the risk model. Thus, we do not believe these differences in
laboratory values and baseline RCA Z scores were likely to
have had an important influence on the analysis. Both the
development and validation data sets were obtained in a
select group of academic medical centers with expertise in
KD. Although our risk score was developed based on
echocardiographic findings in the range of 2 to 8 weeks after
illness onset, it performed well in the VC, in whom the score
was tested on echocardiograms performed 28 to 42 days of
illness (5 weeks). Importantly, in our risk score model, 2%
to 4% of children with a risk score of 0 had CAA, highlighting
that the risk score should not supplant clinician judgment in
individual patients. Finally, the risk score is designed for
assessment of patients with KD at the time of presentation;
risk after presentation should be assessed serially and
therapies adjusted accordingly, as reviewed in the 2017
American Heart Association KD guidelines.
Conclusions
We developed and validated a risk score to predict the
occurrence of CAA within the first 2 to 8 weeks of illness
using 2 North American cohorts of patients with KD. We found
that data obtained routinely at diagnosis, including age, race,
CRP, and coronary artery measurements from baseline
echocardiography, were independently associated with CAA.
Our simple scoring method to delineate 3 groups of children
with KD at low, moderate, and high risk of having CAA at 2 to
8 weeks after illness onset may be a helpful tool to guide
adjunctive anti-inflammatory therapies for primary treatment
and frequency of echocardiographic follow-up. Future studies
should test this risk score in larger and more diverse care
settings in North America to assess accuracy and generaliz-
ability.
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